Given the dual role of YAP – tumor suppression versus tumor promotion – in a cell type-specific manner, TONDU peptide-mediated therapeutic strategy may hold promise only in intestinal cancers that are mediated by the pro-tumorigenic YAP-TEAD complex. This evidence concerns the gene YAP1 and neoplasm.